Showing 1 – 5 of 5
Relevance | Newest | Oldest |
  • Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011

    This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.

  • Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review

    Abstract Full Text
    open access
    ÁñÁ«ÊÓƵ Netw Open. 2023; 6(9):e2336023. 10.1001/jamanetworkopen.2023.36023

    This systematic review assesses the reporting of observational studies that explicitly aimed to emulate target trials, hypothetical randomized trials that could answer causal questions of interest.

  • Assessing the Credibility of Findings From Nonrandomized Studies of Interventions

    Abstract Full Text
    JAMA Cardiol. 2018; 3(10):905-906. 10.1001/jamacardio.2018.2267

    This Viewpoint presents the Risk Of Bias In Nonrandomized Studies of Interventions tool, which permits researchers to compare nonrandomized studies with hypothetical randomized clinical trials.

  • Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2018; 319(9):883-895. 10.1001/jama.2018.0154

    This cluster randomized trial evaluates the effect of a single prostate-specific antigen (PSA) screening test on 10-year prostate cancer–specific mortality among men aged 50 to 69 years treated at UK primary care practices.

  • Oxycodone for Cancer-Related Pain: Meta-analysis of Randomized Controlled Trials

    Abstract Full Text
    free access
    Arch Intern Med. 2006; 166(8):837-843. 10.1001/archinte.166.8.837